BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 29298771)

  • 1. Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all cause mortality: quasi-experimental study.
    Melamed A; Fink G; Wright AA; Keating NL; Gockley AA; Del Carmen MG; Schorge JO; Rauh-Hain JA
    BMJ; 2018 Jan; 360():j5463. PubMed ID: 29298771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk factors for septic adverse events and their impact on survival in advanced ovarian cancer patients treated with neoadjuvant chemotherapy and interval debulking surgery.
    Son JH; Lee JH; Jung JA; Kong TW; Paek J; Chang SJ; Ryu HS
    Gynecol Oncol; 2018 Oct; 151(1):32-38. PubMed ID: 30122310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Primary debulking surgery vs. neoadjuvant chemotherapy followed by interval debulking surgery for patients with advanced ovarian cancer.
    Bian C; Yao K; Li L; Yi T; Zhao X
    Arch Gynecol Obstet; 2016 Jan; 293(1):163-168. PubMed ID: 26198168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary debulking surgery versus neoadjuvant chemotherapy in stage IV ovarian cancer.
    Rauh-Hain JA; Rodriguez N; Growdon WB; Goodman AK; Boruta DM; Horowitz NS; del Carmen MG; Schorge JO
    Ann Surg Oncol; 2012 Mar; 19(3):959-65. PubMed ID: 21994038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ovarian cancer outcomes: Predictors of early death.
    Urban RR; He H; Alfonso R; Hardesty MM; Gray HJ; Goff BA
    Gynecol Oncol; 2016 Mar; 140(3):474-80. PubMed ID: 26743531
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
    Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
    Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer.
    Hinchcliff E; Melamed A; Bregar A; Diver E; Clemmer J; Del Carmen M; Schorge JO; Alejandro Rauh-Hain J
    Gynecol Oncol; 2018 Jan; 148(1):168-173. PubMed ID: 29128105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histopathology predicts clinical outcome in advanced epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and debulking surgery.
    Muraji M; Sudo T; Iwasaki S; Ueno S; Wakahashi S; Yamaguchi S; Fujiwara K; Nishimura R
    Gynecol Oncol; 2013 Dec; 131(3):531-4. PubMed ID: 24096109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical readmission and survival in women with ovarian cancer: Are short-term quality metrics incentivizing decreased long-term survival?
    Barber EL; Rossi EC; Gehrig PA
    Gynecol Oncol; 2017 Dec; 147(3):607-611. PubMed ID: 28941658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone?
    Solmaz U; Mat E; Dereli ML; Turan V; Peker N; Tosun G; Dogan A; Adiyeke M; Ozdemir A; Gungorduk K; Sanci M; Yildirim Y
    J BUON; 2015; 20(3):847-54. PubMed ID: 26214639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer.
    Taşkın S; Güngör M; Ortaç F; Öztuna D
    Arch Gynecol Obstet; 2013 Dec; 288(6):1399-403. PubMed ID: 23775264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer.
    Vogel TJ; Goodman MT; Li AJ; Jeon CY
    Gynecol Oncol; 2017 Aug; 146(2):340-345. PubMed ID: 28596017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of upfront treatment strategies in elderly women with ovarian cancer.
    Wright JD; Ananth CV; Tsui J; Glied SA; Burke WM; Lu YS; Neugut AI; Herzog TJ; Hershman DL
    Cancer; 2014 Apr; 120(8):1246-54. PubMed ID: 24443159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-utility comparison of neoadjuvant chemotherapy versus primary debulking surgery for treatment of advanced-stage ovarian cancer in patients 65 years old or older.
    Rowland MR; Lesnock JL; Farris C; Kelley JL; Krivak TC
    Am J Obstet Gynecol; 2015 Jun; 212(6):763.e1-8. PubMed ID: 25644442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Platinum resistance after neoadjuvant chemotherapy compared to primary surgery in patients with advanced epithelial ovarian carcinoma.
    Rauh-Hain JA; Nitschmann CC; Worley MJ; Bradford LS; Berkowitz RS; Schorge JO; Campos SM; del Carmen MG; Horowitz NS
    Gynecol Oncol; 2013 Apr; 129(1):63-8. PubMed ID: 23337490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does neoadjuvant chemotherapy impair long-term survival for ovarian cancer patients? A nationwide Danish study.
    Fagö-Olsen CL; Ottesen B; Kehlet H; Antonsen SL; Christensen IJ; Markauskas A; Mosgaard BJ; Ottosen C; Soegaard CH; Soegaard-Andersen E; Hoegdall C
    Gynecol Oncol; 2014 Feb; 132(2):292-8. PubMed ID: 24321400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smoking may modify the association between neoadjuvant chemotherapy and survival from ovarian cancer.
    Kelemen LE; Warren GW; Koziak JM; Köbel M; Steed H
    Gynecol Oncol; 2016 Jan; 140(1):124-30. PubMed ID: 26549109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment and outcome of elderly patients with advanced stage ovarian cancer: A nationwide analysis.
    Schuurman MS; Kruitwagen RFPM; Portielje JEA; Roes EM; Lemmens VEPP; van der Aa MA
    Gynecol Oncol; 2018 May; 149(2):270-274. PubMed ID: 29514738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV).
    Glasgow MA; Yu H; Rutherford TJ; Azodi M; Silasi DA; Santin AD; Schwartz PE
    J Surg Oncol; 2013 Feb; 107(2):195-200. PubMed ID: 22648987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in therapy and survival of advanced stage epithelial ovarian cancer patients in the Netherlands.
    van Altena AM; Karim-Kos HE; de Vries E; Kruitwagen RF; Massuger LF; Kiemeney LA
    Gynecol Oncol; 2012 Jun; 125(3):649-54. PubMed ID: 22370602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.